(-0.22%) 5 011.12 points
(0.06%) 37 775 points
(-0.52%) 15 601 points
(-0.18%) $82.54
(1.40%) $1.736
(0.21%) $2 393.30
(-0.30%) $28.32
(-0.54%) $949.00
(0.30%) $0.940
(0.53%) $11.05
(0.15%) $0.804
(-0.17%) $93.90
Live Chart Being Loaded With Signals
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia...
Stats | |
---|---|
Today's Volume | 61.36M |
Average Volume | 6.43M |
Market Cap | 65.07M |
EPS | $0 ( 2024-02-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0315 |
ATR14 | $0.00600 (14.63%) |
Volume Correlation
Incannex Healthcare Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Incannex Healthcare Ltd Correlation - Currency/Commodity
Incannex Healthcare Ltd Financials
Annual | 2022 |
Revenue: | $1.01M |
Gross Profit: | $1.01M (100.00 %) |
EPS: | $-0.0130 |
Q4 | 2022 |
Revenue: | $506 939 |
Gross Profit: | $506 939 (100.00 %) |
EPS: | $-0.00340 |
Q3 | 2022 |
Revenue: | $506 939 |
Gross Profit: | $506 939 (100.00 %) |
EPS: | $-0.00340 |
Q2 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.00310 |
Financial Reports:
No articles found.
Incannex Healthcare Ltd
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators